Physician profile
Stanley L Capper
NPI 1710915210
$7,522.27
in general payments reported to CMS, 2019-2025
38 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $264 · 2021: $1,086 · 2022: $1,431 · 2023: $1,163 · 2024: $1,460 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,397.77 |
| Education | $241.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,929.18 | 2019-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $822.39 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $771.29 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $661.63 | 2019-2025 | |
| Amgen INC. | $621.05 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $446.85 | 2019-2025 | Blu-U, Winlevi |
| Leo Pharma INC. | $386.39 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $314.67 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $187.45 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $187.11 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $161.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $152.06 | 2019-2025 | Libtayo, Dupixent |
| Almirall LLC | $94.47 | 2021-2022 | |
| Pfizer INC. | $84.97 | 2019 | |
| Celgene Corporation | $83.76 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $74.36 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.29 | 2019-2024 | Spevigo |
| Genentech USA, INC. | $55.34 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $53.44 | 2019 | |
| Galderma Laboratories, L.P. | $50.05 | 2024-2025 | Nemluvio |
| Fresenius Kabi USA, LLC | $40.79 | 2023 | Idacio |
| Dermavant Sciences, INC. | $33.61 | 2023 | Vtama |
| Incyte Corporation | $23.03 | 2022 | |
| Kerecis Limited | $20.48 | 2022 | |
| Vyne Pharmaceuticals INC. | $20.05 | 2021 | |
| Kyowa Kirin, INC. | $18.29 | 2023 | Poteligeo |
| Arcutis Biotherapeutics, INC. | $18.08 | 2024 | Zoryve |
| Allergan, INC. | $17.44 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.19 | 2024 | Givlaari |
| Astellas Pharma US INC | $15.64 | 2019 | |
| Mayne Pharma Commercial LLC | $14.57 | 2021 | |
| Tris Pharma INC | $14.28 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.98 | 2023 | Nuzyra |
| Novo Nordisk INC | $13.28 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.10 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.50 | 2019 | |
| Amarin Pharma, INC. | $11.50 | 2019 | |
| Organon LLC | $9.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Capper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.